High materiality7/10
Kymera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Wolfe Research upgrades KYMR to Outperform; Target $180; Posted price $115.43; Price change since signal +1.36%.
- Wolfe Research upgrades KYMR to Outperform; target $180; +1.36% since signal.
Key facts
- 01
Target: $180
- 02
Posted price: $115.43
- 03
Analyst firm: Wolfe Research
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.